Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer

Andrew V Schally, Norman L Block

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Chronic administration of luteinizing hormone-releasing hormone I (LHRH-I) or its agonistic analogs leads to downregulation of pituitary receptors for LHRH, and a gradual suppression of circulating levels of gonadotropins and sex steroids. The creation of a state of sex-hormone deprivation produced by periodic administration of sustained delivery system of LHRH agonists forms the basis of therapy for advanced prostate cancer and other malignant neoplasms. LHRH antagonists developed in recent decades bind competitively to LHRH receptors and cause an immediate inhibition of the release of gonadotropins and sex steroids. This rapid induction of sex-hormone deprivation by LHRH antagonists makes them useful for the treatment of prostate cancer and other sex steroid-dependent cancers. Potent LHRH-I antagonists are finding important clinical applications in urology, oncology, and gynecology. In addition to their suppressive effects on sex-hormone secretion induced by the downregulation of pituitary LHRH receptors, LHRH agonists and antagonists also exert direct inhibitory actions on tumors, which are mediated by tumoral LHRH receptors. These direct actions contribute to the therapeutic effects of LHRH analogs on cancers and in the case LHRH-I antagonists are also utilized for the treatment of benign prostatic hyperplasia (BPH). In this chapter, we review some selected endocrine and antitumoral effects of LHRH agonists and antagonists and clinical trials on prostate cancer and BPH. Experimental studies and early clinical trials with targeted cytotoxic LHRH analogs developed recently for targeted chemotherapy of tumors expressing LHRH receptors are also described.

Original languageEnglish
Title of host publicationDrug Management of Prostate Cancer
PublisherSpringer New York
Pages27-39
Number of pages13
ISBN (Print)9781603278317
DOIs
StatePublished - Dec 1 2010

Fingerprint

Gonadotropin-Releasing Hormone
Prostatic Neoplasms
LHRH Receptors
Gonadal Steroid Hormones
Hormone Antagonists
Steroids
Prostatic Hyperplasia
Neoplasms
Gonadotropins
Down-Regulation
Clinical Trials
Urology
Therapeutic Uses
Gynecology
Therapeutics
Drug Therapy

Keywords

  • Anticancer effects
  • Cell proliferation
  • Chemical castration
  • FSH secretion
  • Gonadotropin
  • LH secretion
  • LHRH-receptor
  • Sex steroid
  • Tumor growth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer. / Schally, Andrew V; Block, Norman L.

Drug Management of Prostate Cancer. Springer New York, 2010. p. 27-39.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schally, Andrew V ; Block, Norman L. / Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer. Drug Management of Prostate Cancer. Springer New York, 2010. pp. 27-39
@inbook{df4e1d952469439b9eff1fb6bad42dd0,
title = "Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer",
abstract = "Chronic administration of luteinizing hormone-releasing hormone I (LHRH-I) or its agonistic analogs leads to downregulation of pituitary receptors for LHRH, and a gradual suppression of circulating levels of gonadotropins and sex steroids. The creation of a state of sex-hormone deprivation produced by periodic administration of sustained delivery system of LHRH agonists forms the basis of therapy for advanced prostate cancer and other malignant neoplasms. LHRH antagonists developed in recent decades bind competitively to LHRH receptors and cause an immediate inhibition of the release of gonadotropins and sex steroids. This rapid induction of sex-hormone deprivation by LHRH antagonists makes them useful for the treatment of prostate cancer and other sex steroid-dependent cancers. Potent LHRH-I antagonists are finding important clinical applications in urology, oncology, and gynecology. In addition to their suppressive effects on sex-hormone secretion induced by the downregulation of pituitary LHRH receptors, LHRH agonists and antagonists also exert direct inhibitory actions on tumors, which are mediated by tumoral LHRH receptors. These direct actions contribute to the therapeutic effects of LHRH analogs on cancers and in the case LHRH-I antagonists are also utilized for the treatment of benign prostatic hyperplasia (BPH). In this chapter, we review some selected endocrine and antitumoral effects of LHRH agonists and antagonists and clinical trials on prostate cancer and BPH. Experimental studies and early clinical trials with targeted cytotoxic LHRH analogs developed recently for targeted chemotherapy of tumors expressing LHRH receptors are also described.",
keywords = "Anticancer effects, Cell proliferation, Chemical castration, FSH secretion, Gonadotropin, LH secretion, LHRH-receptor, Sex steroid, Tumor growth",
author = "Schally, {Andrew V} and Block, {Norman L}",
year = "2010",
month = "12",
day = "1",
doi = "10.1007/978-1-60327-829-4_2",
language = "English",
isbn = "9781603278317",
pages = "27--39",
booktitle = "Drug Management of Prostate Cancer",
publisher = "Springer New York",

}

TY - CHAP

T1 - Luteinizing hormone-releasing hormone and its agonistic, antagonistic, and targeted cytotoxic analogs in prostate cancer

AU - Schally, Andrew V

AU - Block, Norman L

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Chronic administration of luteinizing hormone-releasing hormone I (LHRH-I) or its agonistic analogs leads to downregulation of pituitary receptors for LHRH, and a gradual suppression of circulating levels of gonadotropins and sex steroids. The creation of a state of sex-hormone deprivation produced by periodic administration of sustained delivery system of LHRH agonists forms the basis of therapy for advanced prostate cancer and other malignant neoplasms. LHRH antagonists developed in recent decades bind competitively to LHRH receptors and cause an immediate inhibition of the release of gonadotropins and sex steroids. This rapid induction of sex-hormone deprivation by LHRH antagonists makes them useful for the treatment of prostate cancer and other sex steroid-dependent cancers. Potent LHRH-I antagonists are finding important clinical applications in urology, oncology, and gynecology. In addition to their suppressive effects on sex-hormone secretion induced by the downregulation of pituitary LHRH receptors, LHRH agonists and antagonists also exert direct inhibitory actions on tumors, which are mediated by tumoral LHRH receptors. These direct actions contribute to the therapeutic effects of LHRH analogs on cancers and in the case LHRH-I antagonists are also utilized for the treatment of benign prostatic hyperplasia (BPH). In this chapter, we review some selected endocrine and antitumoral effects of LHRH agonists and antagonists and clinical trials on prostate cancer and BPH. Experimental studies and early clinical trials with targeted cytotoxic LHRH analogs developed recently for targeted chemotherapy of tumors expressing LHRH receptors are also described.

AB - Chronic administration of luteinizing hormone-releasing hormone I (LHRH-I) or its agonistic analogs leads to downregulation of pituitary receptors for LHRH, and a gradual suppression of circulating levels of gonadotropins and sex steroids. The creation of a state of sex-hormone deprivation produced by periodic administration of sustained delivery system of LHRH agonists forms the basis of therapy for advanced prostate cancer and other malignant neoplasms. LHRH antagonists developed in recent decades bind competitively to LHRH receptors and cause an immediate inhibition of the release of gonadotropins and sex steroids. This rapid induction of sex-hormone deprivation by LHRH antagonists makes them useful for the treatment of prostate cancer and other sex steroid-dependent cancers. Potent LHRH-I antagonists are finding important clinical applications in urology, oncology, and gynecology. In addition to their suppressive effects on sex-hormone secretion induced by the downregulation of pituitary LHRH receptors, LHRH agonists and antagonists also exert direct inhibitory actions on tumors, which are mediated by tumoral LHRH receptors. These direct actions contribute to the therapeutic effects of LHRH analogs on cancers and in the case LHRH-I antagonists are also utilized for the treatment of benign prostatic hyperplasia (BPH). In this chapter, we review some selected endocrine and antitumoral effects of LHRH agonists and antagonists and clinical trials on prostate cancer and BPH. Experimental studies and early clinical trials with targeted cytotoxic LHRH analogs developed recently for targeted chemotherapy of tumors expressing LHRH receptors are also described.

KW - Anticancer effects

KW - Cell proliferation

KW - Chemical castration

KW - FSH secretion

KW - Gonadotropin

KW - LH secretion

KW - LHRH-receptor

KW - Sex steroid

KW - Tumor growth

UR - http://www.scopus.com/inward/record.url?scp=84891380385&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891380385&partnerID=8YFLogxK

U2 - 10.1007/978-1-60327-829-4_2

DO - 10.1007/978-1-60327-829-4_2

M3 - Chapter

SN - 9781603278317

SP - 27

EP - 39

BT - Drug Management of Prostate Cancer

PB - Springer New York

ER -